ArticleMedicine2026
Macrolide resistance and risk factors for refractory Mycoplasma pneumoniae pneumonia in pediatric patients from Wuhu, China: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aimed to assess macrolide resistance and the genotype distribution of Mycoplasma pneumoniae (MP) in children and identify the risk factors for refractory MP pneumonia (RMPP) during the initial post-COVID-19 outbreak in Wuhu. This retrospective study enrolled children with MPP in Wuhu (November 2023-May 2024). Using preserved nasopharyngeal swabs, macrolide resistance mutations were identified by sequencing the 23S rRNA domain V, and genotyping was performed by PCR. Clinical and laboratory parameters were analyzed to identify the risk factors associated with RMPP. An analysis of 296 pediatric MPP patients revealed universal cough (100%), with high rates of fever (94.93%) and sputum (71.62%). Common findings included moist rales (53.04%) and lobar pneumonia (37.5%). Genotype I (87.84%) predominated and showed a higher A2063G resistance mutation rate than genotype II (74.23% vs 55.56%, P = .019). This mutation was associated with longer hospitalization, more vomiting, and higher C-reactive protein (CRP). RMPP (69.26%) was notable for producing more severe symptoms, higher inflammatory markers (CRP, lactate dehydrogenase [LDH], procalcitonin [PCT], D-D dimer), and a greater need for bronchoscopy and steroid use. Multivariate logistic regression identified prolonged hospitalization, the presence of pulmonary infiltrates, CRP > 10 mg/L, LDH > 246 U/L, and D-D dimer > 0.50 μg/mL as independent risk factors for RMPP. Subsequent receiver operating characteristic curve analysis demonstrated the predictive utility of D-D dimer and LDH levels. The present study established genotype I MP with A2063G-mediated macrolide resistance as the predominant epidemic variant in Wuhu. Independent risk factors for RMPP included a prolonged hospital stay and elevated CRP, LDH and D-D dimer. LDH combined with D-D dimer served as a valuable co-marker for early risk stratification and prediction of refractory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.